MedTrace Logo

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

NCT06228053 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-12-22

No results posted yet for this study

Summary

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

Conditions

Interventions

DRUG

SX-682

Specified dose twice daily

DRUG

Enzalutamide

Specified dose once daily

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Syntrix Biosystems, Inc.

    lead INDUSTRY

Principal Investigators

  • Syntrix Biosystems · Syntrix Biosystems, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-18
Primary Completion
2026-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06228053 on ClinicalTrials.gov